You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of anovel dry powder delivery system for delivery of inhaled corticosteroids to the small airways of pediatric asthma patients
SBC: Respira Therapeutics, Inc. Topic: NICHDABSTRACT Asthma is prevalent in overof the pediatric populationwith most pediatric patients uncontrolled or poorly controlled in their diseaseExtensive inflammation of the airways in asthma is treated using inhaled corticosteroidsICSas a maintenance therapyHoweverthese drugs can suppress growth in childrenand fear of this outcome can lead to non adherence in pediatric patientsThis results in sever ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
High-Throughput Spheroid Screening Platform
SBC: BennuBio Inc Topic: 400PROJECT SUMMARYThis proposal will develop the High-Throughput Spheroid Screening Platform (HTSSP) to create an entirely new tool to study cell-cell interactions and microenvironmental stresses that occur in tissues and tumors. Such interactions are critical in the pharmaceutical response of cells within tissues, but current methods do not allow high throughput screening (HTS) of cellular responses ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Laboratory Bench-Top EXAFS with STJ Spectrometer
SBC: STAR CRYOELECTRONICS, LLC Topic: 400PROJECT SUMMARY Extended X-ray absorption fine structure (EXAFS) spectroscopy is a technique that gives element-specific structural and chemical information about molecules. An enormous advantage of EXAFS spectroscopy is that it is readily applied to many different kinds of sample, including, solutions, powders, slurries, and animal tissues. Current EXAFS instruments require bright X-ray beams fro ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Malarial Retinopathy Screening System for Improved Diagnosis of Cerebral Malaria
SBC: VisionQuest Biomedical Inc Topic: NIAIDSummary Cerebral malaria (CM) is a life-threatening clinical syndrome associated with malarial infection. Annually, malaria affects more than 200 million people and claims the lives of over 440,000 people worldwide, mostly African children. As a consequence of the high incidence of CM, it is often misdiagnosed for other pathologies with similar symptoms, leading to a high false positive rate for C ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
SBC: Agilvax, Inc. Topic: 102Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting cancer stem cells (CSC) that is designed for use in combination with existing and emerging therapie ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF NEW ANTI-FELINE LEUKEMIA VIRUS DRUGS
SBC: ALBUQUERQUE AVIAN EXOTIC Topic: N/AIN COLLABORATIVE STUDIES WITH THE UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE, WE HAVE OBTAINED PRELIMINARY DATA ON THE ANTIVIRAL PROPERTIES OF DERIVATIVES OF THE NATURAL PRODUCT GOSSYPOL. IN PARTICULAR, ONE DERIVATIVE NAMED GIL HAS SHOW PROMISING ACTIVITY IN THE TREATMENTOF DOMESTIC CATS INFECTED WITH FELINE LEUKEMIA VIRUS (FELV). ALSO NOTEWORTHY IS THE FACT THAT GIL SHOWS PROMISING IN VITRO ACTI ...
SBIR Phase I 1992 Department of Health and Human Services -
SILENT PUMP FOR LASER SMOKE REMOVAL AND STERILIZATION
SBC: Ballena Systems Corp Topic: N/AA SMOKE EVACUATION SYSTEM IS AN ESSENTIAL PART OF LASER SURGERY, BOTH IN RESEARCH AS WELL AS IN HUMAN SURGERY. CURRENT TECHNIQUES FOR THE REMOVAL OF SMOKE AND DEBRIS GENERATED DURING LASER SURGERY ARE INEFFICIENT, NOISY, AND EXPOSE THE SURGEONS AND SUPPORT PERSONNEL TO THE HAZARDS OF PATHOLOGICAL AIRBORNE AEROSOLS. THE AIRBORNE AEROSOLS ARE CURRENTLY REMOVED THROUGH VACUUM ACTION (AIR PUMPS) AND C ...
SBIR Phase I 1992 Department of Health and Human Services -
DIRECT RADIOMETAL LABELING FOR IMAGING AND THERAPY
SBC: Rhomed, Inc. Topic: N/AANTIBODIES OR ANTIBODY FRAGMENTS, REDUCED AND LYOPHILIZED FOR USE IN PREPARING INSTANT, ONE-STEP TC-99M RADIOPHARMACEUTICALS, CAN ALSO BE LABELED WITH CU-67. THE CU-67, AS CU(II) IN A PH 5.6 BUFFER, IS SIMPLY ADDED TO THE ANTIBODY TO GENERATE THE CU-67-LABELED ANTIBODY. THE PURPOSE OF THIS PROJECT IS TO DETERMINE THE PARAMETERS OF THIS REACTION AND THE PURITY, STABILITY, AND IMMUNO-REACTIVITY OF T ...
SBIR Phase I 1992 Department of Health and Human Services -
OPPORTUNISTIC INFECTION IMAGING IN AIDS
SBC: Rhomed, Inc. Topic: N/AOPPORTUNISTIC INFECTIONS ARE A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN AIDS PATIENTS. ALTHOUGH IT IS GENERALLY BELIEVED THAT THE EARLY DIAGNOSIS AND TREATMENT OF AN OPPORTUNISTIC INFECTION IS CRITICAL TO DECREASING MORBIDITY AND INCREASING OVERALL SURVIVAL, LOCALIZING THE SITE OF THESE INFECTIONS IS OFTEN DIFFICULT. CURRENTLY, THERE ARE TWO ACCEPTED TECHNIQUES FOR WHOLE-BODY EVALUATION USING RAD ...
SBIR Phase I 1992 Department of Health and Human Services -
TC-99M-LABELED CHEMOTACTIC PEPTIDES FOR ABSCESS IMAGING
SBC: Rhomed, Inc. Topic: N/AFORMULATED CHEMOTACTIC PEPTIDES, WITH ENDOGENOUS TC-99M BINDING SITES, WILL BE DEVELOPED FOR USE IN LOCALIZING ABSCESSES, INFLAMMATIONS, AND INFECTIONS. THE PEPTIDES ARE DESIGNED TO HAVE THE BIOLOGICAL FUNCTION LOCATED AT ONE END OF THE MOLECULE, AND THE TC-99M BINDING SITE AT THE OTHER END OF THE MOLECULE. IN PHASE I THE CHEMOTACTIC PEPTIDE ANALOGS WILL BE FORMULATED IN SINGLE-STEP, DIRECT LABELI ...
SBIR Phase I 1992 Department of Health and Human Services